THANK YOU FOR SUBSCRIBING
Antengene Clinical has collaborated with Bristol Myers Squibb to examine ATG-017 in combination with Opdivo in Advanced Solid Tumors.
FREMONT, CA: Antengene Corporation Limited announced today a clinical trial collaboration for safety evaluation, pharmacokinetics, and preliminary efficiency of ATG-017 along with Bristol Myers Squibb's PD-1 checkpoint inhibitor, Opdivo (nivolumab). Antengene is a leading innovative global biopharmaceutical company committed to discovering, developing, and commercializing first/best-in-class medicines for cancer and other life-threatening diseases. The combination will be evaluated as a potential therapeutic option for patients with advanced solid tumors in the open-label Phase 1/2 trial. Jay Mei, M.D., Ph.D., Antengene's Founder and CEO, stated that their trial partnership with Bristol Myers Squibb shows Antengene's dedication to exploring combination regimens from their portfolio with other mechanisms of action may improve cancer care. He also shared how thrilled they were to begin this trial collaboration with Bristol Myers Squibb. They look forward to starting enrollment in this innovative combination regimen in the first half of 2022.
Opdivo is a human programmed death receptor-1 (PD-1) blocking antibody that binds to the PD-1 receptor on activated T cells, and ATG-017 is a selective oral inhibitor of extracellular signal-regulated protein kinase 1 and 2 (ERK1/2). This collaboration builds on Antengene's preclinical data set, demonstrating that the combination of an ERK1/2 inhibitor and an immune checkpoint inhibitor (CPI) produced synergistic efficiency in preclinical immune CPI-resistant cancer models, some of which was presented at the Society for Immunotherapy in Cancer (SITC) 2021. Antengene's Chief Medical Officer, Kevin Lynch, M.D, expressed that Antengene thinks that a sensible combination of targeted therapies and immuno-oncology medications has the best potential of success in future cancer treatment advances. He added that they also believe ATG-017 can be effective in various combination regimens. The combination of ATG-017 with an immune CPI showed remarkable synergy in resistant and refractory murine tumor models in preclinical examinations.